Related Experiment Videos
Cycloserine-induced lichenoid drug eruption
1Department of Dermatology, Catholic University Medical College, Seoul, Korea.
Dermatology (Basel, Switzerland)
|January 1, 1995
Summary
A rare skin reaction, lichenoid drug eruption, was observed in a patient treated with cycloserine, an antituberculous drug. Discontinuation of cycloserine led to the resolution of the patient's skin lesions.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Tuberculosis (TB) treatment commonly involves multiple drugs.
- Cycloserine is a second-line antitubercular agent used for multidrug-resistant TB.
- Adverse cutaneous reactions to antitubercular drugs are known but vary in frequency.
Observation:
- A 65-year-old male developed pruritic, violaceous, flat-topped papules and plaques on his back after 5 months of antitubercular therapy including cycloserine.
- Histopathology confirmed a lichenoid drug eruption.
- Patch testing identified cycloserine as the causative agent.
Findings:
- The patient's skin lesions and pruritus resolved completely within 4 months of discontinuing oral cycloserine.
- This case represents the first reported instance of a lichenoid drug eruption specifically linked to cycloserine use.
Implications:
- This report highlights the potential for cycloserine to induce rare but distinct skin reactions.
- Clinicians should consider cycloserine as a potential cause of lichenoid drug eruptions in patients undergoing TB treatment.
- Further pharmacovigilance is warranted to fully understand the dermatological side effect profile of cycloserine.